Unknown

Dataset Information

0

Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors.


ABSTRACT:

Background & aim

To compare the efficacy of pegylated-interferon (Peg-IFN) ?-2a or ?-2b and ribavirin given as dual therapy versus triple therapy (Peg-IFN and ribavirin plus boceprevir or telaprevir) in patients with HCV-1 chronic hepatitis naïve for anti-HCV therapy or relapsers to dual therapy in relation to the presence of constitutional, clinical and virological predictors of treatment response.

Methods

Included in the meta-analysis were studies meeting these criteria: original data from randomized trials on the efficacy of dual versus triple therapy in therapy-naïve patients or relapsers; at least one primary outcome clearly defined: sustained virological response in patients with or without rapid virological response (RVR), with genotype 1a or 1b, low or high HCV load, IL28-B CC or non-CC genotype, mild or severe fibrosis; odds ratio estimates of relative risk (RR) and 95% confidence intervals; English language; and published up to the end of June 2013.

Results

Seven original studies met the inclusion criteria, allowing a meta-analysis on 3,652 patients. Triple therapy was more effective than dual, regardless of IL-28B genotype, HCV sub-genotype, liver fibrosis, and baseline HCV load. In 1,045 patients who achieved RVR, SVR was more frequently achieved with dual therapy (RR = 1.11; p = 0.002) than triple. The same results were achieved when only the therapy-naïve patients were considered.

Conclusions

Triple therapy provides a significantly higher SVR rate than dual therapy, but dual therapy obtains a significantly higher SVR rate in patients with RVR. The data stress the clinical importance of a 4-week lead-in phase in direct-acting antiviral-based treatment.

SUBMITTER: Coppola N 

PROVIDER: S-EPMC3984165 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors.

Coppola Nicola N   Pisaturo Mariantonietta M   Sagnelli Caterina C   Sagnelli Evangelista E   Angelillo Italo F IF  

PloS one 20140411 4


<h4>Background & aim</h4>To compare the efficacy of pegylated-interferon (Peg-IFN) α-2a or α-2b and ribavirin given as dual therapy versus triple therapy (Peg-IFN and ribavirin plus boceprevir or telaprevir) in patients with HCV-1 chronic hepatitis naïve for anti-HCV therapy or relapsers to dual therapy in relation to the presence of constitutional, clinical and virological predictors of treatment response.<h4>Methods</h4>Included in the meta-analysis were studies meeting these criteria: origina  ...[more]

Similar Datasets

| S-EPMC4670956 | biostudies-literature
| S-EPMC4671604 | biostudies-literature
| S-EPMC4806200 | biostudies-literature
| S-EPMC4727992 | biostudies-literature
| S-EPMC3041922 | biostudies-literature
| S-EPMC3743300 | biostudies-literature
| S-EPMC4386819 | biostudies-literature
| S-EPMC4282353 | biostudies-literature
| S-EPMC3766849 | biostudies-literature
| S-EPMC5552231 | biostudies-literature